Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer

Arai, Hiroyuki; Millstein, Joshua; Loupakis, Fotios; Stintzing, Sebastian; Wang, Jingyuan; Battaglin, Francesca; Kawanishi, Natsuko; Jayachandran, Priya; Soni, Shivani; Zhang, Wu; Mumenthaler, Shannon M.; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo und Lenz, Heinz-Josef (2021): Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. In: European Journal of Cancer, Bd. 150: S. 133-142

Abstract

(FOLFIRI/bevacizumab arm in TRIBE, n = 215). Genomic DNA extracted from blood sam-ples was genotyped, and ten SNPs were tested for association with clinical outcomes. Results: In the cetuximab cohort, four SNPs were significantly associated with progression -free survival in univariate analysis: NANOG rs11055767 (any A allele vs C/C, hazard ratio [HR] = 0.62, 95% confidence interval [CI] = 0.42-0.94, p = 0.02), NANOG rs10744044 (any A allele vs G/G, HR = 0.59, 95% CI = 0.39-0.90, p = 0.01), NANOGP8 rs2168958 (any C allele vs A/A, HR = 2.12, 95% CI = 1.36-3. 29, p < 0.001) and NANOGP8 rs2279066 (any C allele vs T/T, HR = 1.80, 95% CI = 1.06-1.68, p = 0.03). Multivariate analysis confirmed the significant associations for NANOGP8 rs2168958 and NANOGP8 rs2279066. In either bevacizumab cohort, no significant associations were observed in univar-iate analysis. Conclusions: Germ line polymorphisms in the PTF genes could be predictive markers for ce-tuximab in mCRC. Published by Elsevier Ltd.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0959-8049
• Sprache: Englisch